| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
|
Lancet Oncol
|
2015
|
2.44
|
|
2
|
Molecular pathogenesis of chronic lymphocytic leukemia.
|
J Clin Invest
|
2012
|
1.64
|
|
3
|
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study.
|
Lancet Oncol
|
2015
|
1.47
|
|
4
|
Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia.
|
Elife
|
2014
|
0.95
|
|
5
|
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
|
Lancet Oncol
|
2016
|
0.92
|
|
6
|
Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia.
|
Haematologica
|
2016
|
0.85
|
|
7
|
Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?
|
Haematologica
|
2016
|
0.81
|
|
8
|
Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance.
|
Blood
|
2014
|
0.81
|
|
9
|
Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival.
|
Oncotarget
|
2015
|
0.80
|
|
10
|
RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
|
Haematologica
|
2016
|
0.79
|
|
11
|
Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study.
|
Drug Des Devel Ther
|
2015
|
0.76
|
|
12
|
Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.
|
Br J Clin Pharmacol
|
2015
|
0.76
|
|
13
|
Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.
|
Cancer Res
|
2017
|
0.75
|
|
14
|
MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.
|
Haematologica
|
2014
|
0.75
|
|
15
|
Richter syndrome: pathogenesis and management.
|
Semin Oncol
|
2016
|
0.75
|